Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

WATERTOWN, MASS., JULY 31, 2026 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026.

WEREWOLF THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

WATERTOWN, MASS., MAY 07, 2026 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

WEREWOLF THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

COMPANY CONTINUES TO EVALUATE STRATEGIC OPTIONS TO MAXIMIZE SHAREHOLDER VALUE COMPANY CONTINUES TO EVALUATE STRATEGIC OPTIONS TO MAXIMIZE SHAREHOLDER VALUE

WEREWOLF THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND RECENT CORPORATE UPDATES

WATERTOWN, MASS., FEB. 24, 2026 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (NASDAQ: HOWL) (THE COMPANY OR WEREWOLF), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT THE COMPANY WILL EXPLORE A FULL RANGE OF STRATEGIC ALTERNATIVES TO ADVANCE ITS PROMISING PLATFORM AND DRUG DEVELOPMENT PIPELINE TO MAXIMIZE STOCKHOLDER VALUE. THE COMPANY HAS ENGAGED PIPER SANDLER & CO. (PIPER SANDLER) TO SERVE AS EXCLUSIVE FINANCIAL ADVISOR TO ASSIST IN THE STRATEGIC EVALUATION PROCESS.

WEREWOLF THERAPEUTICS ANNOUNCES PLAN TO EXPLORE STRATEGIC ALTERNATIVES

WTX-124 INITIAL PHASE 1B EXPANSION ARM DATA SHOWED 30% OVERALL RESPONSE RATE AS A MONOTHERAPY IN A DEFINED SUBSET OF POST-ICI ADVANCED OR METASTATIC CUTANEOUS MELANOMA PATIENTS, WITH POTENTIAL BEST-IN-CLASS TOLERABILITY PROFILE WTX-330 PHASE 1B/2 TRIAL INITIAL DATA DEMONSTRATED ADDITIONAL EVIDENCE OF ANTITUMOR ACTIVITY AND HIGHLY FAVORABLE TOLERABILITY PROFILE, BUILDING UPON MONOTHERAPY ACTIVITY DEMONSTRATED IN FIRST-IN-HUMAN PHASE 1 CLINICAL TRIAL ADDITIONAL PHASE 1/1B DATA UPDATE FOR WTX-124 AND COMPLETION OF PART A OF PHASE 1B/2 CLINICAL TRIAL FOR WTX-330 ARE BOTH EXPECTED IN THE FIRST HALF OF 2026 WTX-1011, WEREWOLF'S FIRST NOMINATED INDUCERT CELL ENGAGER DEVELOPMENT CANDIDATE TARGETING ADVANCED, RELAPSED/REFRACTORY STEAP1-EXPRESSING CANCERS, CONTINUES TO PROGRESS TOWARDS IND; WITH THE ANNOUNCEMENT OF WEREWOLF'S SECOND INDUCER DEVELOPMENT CANDIDATE, WTX-2022, TARGETING CDH6-EXPRESSING CANCERS, WEREWOLF IS NOW PLANNING FOR TWO INDS BY MID-2027 WATERTOWN, MASS., DEC. 18, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (NASDAQ: HOWL) (THE COMPANY OR WEREWOLF), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED A PIPELINE UPDATE, INCLUDING A REVIEW OF RECENT DATA FOR ITS INDUKINEPROGRAMS, AND A BUSINESS OVERVIEW OF ITS PRIORITIES FOR 2026 THAT INCLUDES A FOCUS ON THE COMPANY'S HIGHLY DIFFERENTIATED INDUCER T CELL ENGAGER PLATFORM.

WEREWOLF THERAPEUTICS ANNOUNCES PIPELINE AND BUSINESS UPDATES

NOVEL INDUCER T CELL ENGAGER PLATFORM DESIGNED TO MITIGATE SYSTEMIC TOXICITIES SEQUENTIAL DOSING OF INDUKINE MOLECULES IN PRECLINICAL MODEL SHOWED POTENT ANTITUMOR ACTIVITY WITH IMPROVED SAFETY FIRST-IN-KIND REAL-TIME PHARMACOKINETIC DATA IN A MOUSE TUMOR MODEL CONFIRMED WTX-124 SELECTIVE ACTIVATION IN TUMORS, SPARING HEALTHY TISSUE WATERTOWN, MASS., NOV. 07, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY SHARED PRECLINICAL DATA AT THE 2025 SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND.

WEREWOLF THERAPEUTICS PRESENTS DATA EXPANDING ITS PREDATOR PLATFORM AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

 UPDATE ON WTX-124 PHASE 1/1B CLINICAL TRIAL INTERIM DATA AND END OF PHASE 1 MEETING WITH THE U.S. FOOD & DRUG ADMINISTRATION (FDA) IS EXPECTED TO BE PROVIDED LATER IN THE FOURTH QUARTER OF 2025   UPDATE ON PHASE 1B/2 CLINICAL TRIAL OF WTX-330 AND POTENTIAL FURTHER DEVELOPMENT PLAN IS EXPECTED TO BE PROVIDED LATER IN THE FOURTH QUARTER OF 2025   WTX-1011, COMPANY'S FIRST INDUCER  T-CELL ENGAGER DEVELOPMENT CANDIDATE TARGETING STEAP1, CONTINUES IND-ENABLING STUDIES  WATERTOWN, MASS., NOV. 04, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

WEREWOLF THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WATERTOWN, MASS., OCT. 03, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT THREE POSTERS WILL BE PRESENTED AT THE UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING, TAKING PLACE NOVEMBER 5-9, 2025, IN NATIONAL HARBOR, MARYLAND. DETAILS FOR THE POSTER PRESENTATIONS ARE AS FOLLOWS:

WEREWOLF THERAPEUTICS TO PRESENT POSTERS AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER'S (SITC) 40TH ANNUAL MEETING

WATERTOWN, MASS., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY ANNOUNCED THAT DANIEL J.

WEREWOLF THERAPEUTICS TO PARTICIPATE IN THE UPCOMING H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

 WTX-124 PHASE 1/1B CLINICAL TRIAL ON TRACK FOR INTERIM DATA READOUT IN THE FOURTH QUARTER OF 2025, INCLUDING PATIENTS IN BOTH THE MONOTHERAPY AND COMBINATION EXPANSION ARMS OF CUTANEOUS MELANOMA AND RENAL CELL CARCINOMA   PLANNING TO ENGAGE WITH U.S. FOOD & DRUG ADMINISTRATION (FDA) IN THE SECOND HALF OF 2025 TO DISCUSS POTENTIAL REGISTRATIONAL PATHWAYS FOR WTX-124 IN ADVANCED OR METASTATIC CUTANEOUS MELANOMA   PHASE 1B/2 CLINICAL TRIAL OF WTX-330 IS ACTIVELY ENROLLING, WITH ANTICIPATED DETERMINATION OF DOSING REGIMEN BY THE END OF 2025   COMPANY ANNOUNCES WTX-1011, ITS FIRST INDUCER  T-CELL ENGAGER DEVELOPMENT CANDIDATE, TARGETING STEAP1  WATERTOWN, MASS., AUG. 14, 2025 (GLOBE NEWSWIRE) -- WEREWOLF THERAPEUTICS, INC. (THE COMPANY OR WEREWOLF) (NASDAQ: HOWL), AN INNOVATIVE BIOPHARMACEUTICAL COMPANY PIONEERING THE DEVELOPMENT OF CONDITIONALLY ACTIVATED THERAPEUTICS ENGINEERED TO STIMULATE THE BODY'S IMMUNE SYSTEM FOR THE TREATMENT OF CANCER AND OTHER IMMUNE-MEDIATED CONDITIONS, TODAY PROVIDED A BUSINESS UPDATE AND REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025.

Werewolf Therapeutics, Inc.

HOWL

Price

Financial Reports

No items found.

Press Releases

Werewolf Therapeutics, Inc.

HOWL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

HOWL